0001209191-23-053791.txt : 20231027 0001209191-23-053791.hdr.sgml : 20231027 20231027174329 ACCESSION NUMBER: 0001209191-23-053791 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231025 FILED AS OF DATE: 20231027 DATE AS OF CHANGE: 20231027 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Castelein Caley CENTRAL INDEX KEY: 0001355758 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40384 FILM NUMBER: 231356561 MAIL ADDRESS: STREET 1: THOM. WEISEL HEALTHCARE VENTURES STREET 2: ONE MONTGOMERY STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tourmaline Bio, Inc. CENTRAL INDEX KEY: 0001827506 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 27 WEST 24TH STREET STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 646-481-9832 MAIL ADDRESS: STREET 1: 27 WEST 24TH STREET STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Talaris Therapeutics, Inc. DATE OF NAME CHANGE: 20201007 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-25 0 0001827506 Tourmaline Bio, Inc. TRML 0001355758 Castelein Caley C/O TOURMALINE BIO, INC. 27 WEST 24TH STREET, SUITE 702 NEW YORK NY 10010 1 0 0 0 0 Common Stock 2023-10-25 4 P 0 4200 12.07 A 500719 D Common Stock 2023-10-27 4 P 0 15800 14.55 A 516519 D Common Stock 458039 I By KVP Capital, LP The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.82 to $12.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. These shares are held by KVP Capital, LP ("KVP"). The Reporting Person is the Managing Member of KVP Capital GP, LLC, the General Partner of KVP and, as such, has sole voting and investment power with respect to the shares held by KVP. The Reporting Person disclaims beneficial ownership of the shares held by KVP except to the extent of his pecuniary interest therein and this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. /s/ Brad Middlekauff, Attorney-in-Fact 2023-10-27